<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99135">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01893658</url>
  </required_header>
  <id_info>
    <org_study_id>12-006797</org_study_id>
    <nct_id>NCT01893658</nct_id>
  </id_info>
  <brief_title>Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)</brief_title>
  <official_title>Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators goal is to evaluate the role of XOLAIR® in treatment of Acute
      Tubulointerstitial Nephritis (AIN) with the goal of shortening the duration and dose of
      prednisone for treatment of drug-induced AIN. Currently there is no good treatment for
      drug-induced AIN. Prednisone is the standard treatment but is associated with many
      side-effects when used long-term and at high doses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in serum creatinine</measure>
    <time_frame>Baseline to three months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean individual percentage drop in serum creatinine relative to entry creatinine levels</measure>
    <time_frame>baseline to 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects returning to their usual baseline creatinine (+25%) or below</measure>
    <time_frame>baseline to 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Neutrophil gelatinase-associated lipocalcin.</measure>
    <time_frame>baseline to 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>24 hours, 4 hours, and in 3 months after Xolair treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects requiring renal replacement therapy</measure>
    <time_frame>baseline to 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Interstitial Nephritis</condition>
  <arm_group>
    <arm_group_label>Omalizumab and Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omalizumab in addition to prednisone. Omalizumab will be given once subcutaneously at a dose of 375 mg within 24 hours after receiving prednisone
Standard clinical therapy with prednisone.
Day 1-14: 60 mg/day 14 days (2 weeks)
Day 15-28: 40 mg/day (2 weeks)
Day 29-35: 30 mg/day (1 week)
Day 36-42: 20 mg/day (1 week)
Day 43-49: 10 mg/day (1 week)
Day 50-56:  5 mg/day (1 week)
Subjects will stop taking prednisone on day 57
If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard clinical therapy with prednisone.
Day 1-14: 60 mg/day 14 days (2 weeks)
Day 15-28: 40 mg/day (2 weeks)
Day 29-35: 30 mg/day (1 week)
Day 36-42: 20 mg/day (1 week)
Day 43-49: 10 mg/day (1 week)
Day 50-56:  5 mg/day (1 week)
Subjects will stop taking prednisone on day 57
If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <arm_group_label>Omalizumab and Prednisone</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Omalizumab and Prednisone</arm_group_label>
    <arm_group_label>Prednisone</arm_group_label>
    <other_name>Prednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult subjects &gt; 18 years old of both genders

          2. Biopsy proven acute interstitial nephritis in the native kidneys without evidence of
             ischemic or glomerular pathology in the biopsy

          3. Normal baseline creatinine defined as estimated GFR ≥ 60 ml/min/SA based on MDRD
             calculation within 1 year prior to renal biopsy

          4. Serum creatinine elevation of &gt; 0.3 mg/dL and/or doubling of serum creatinine
             compared to most recent documented creatinine available (at least within the last
             year)

          5. No immunosuppressants in the last three months including prednisone

          6. Women of childbearing potential not using the contraception method can be included as
             this is a one time dosing and has no known long-term effects.

        Exclusion Criteria:

          1. Unwillingness to give consent

          2. Patients who are Pregnant (positive serum pregnancy test for females) or breast
             feeding

          3. Documented history of an autoimmune disease

          4. Inability or unwillingness to take prednisone for the prescribed duration and/or dose

          5. Subjects suspected to have non-drug-induced AIN

          6. Subjects not meeting the inclusion criteria

          7. Subjects with contraindication to administration of omalizumab

          8. Prior use of omalizumab

          9. Severe hypersensitivity to omalizumab or any component of the product

         10. Known elevated IgE level from other disease processes

         11. Subjects taking (nonsteroidal antiinflammatory drug) NSAIDs chronically

         12. Use of any other investigational agents in the last 30 days

         13. Patients with severe medical condition(s) including metastatic cancer, terminal
             congestive heart failure, severe ischemic heart disease or any other medical
             condition in which life expectancy is less than 6 months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vesna D. Garovic, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanne D. Ryan</last_name>
    <phone>507-266-8668</phone>
    <email>ryan.joanne@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen S Mieras, CCRP</last_name>
    <phone>507-284-9187</phone>
    <email>mieras.kathleen@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne D. Ryan</last_name>
      <phone>507-266-8668</phone>
      <email>ryan.joanne@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen S. Mieras, CCRP</last_name>
      <phone>507-284-9187</phone>
      <email>mieras.kathleen@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ladan Zand, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaiser Lim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vesna D. Garovic, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 22, 2014</lastchanged_date>
  <firstreceived_date>June 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Vesna D. Garovic, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Interstitial Nephritis</keyword>
  <keyword>Nephritis</keyword>
  <keyword>Tubulointerstitial</keyword>
  <keyword>Renal disease</keyword>
  <keyword>Kidney</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Nephritis, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
